PAVmed develops medical devices, diagnostics and digital health tools, including the EsoGuard test for esophageal precancer screening. It last closed at $1.47 on Nov 17, down 16.29% on the day.
Only 1 firm rated PAVM in the past 90 days, not enough for a consensus
Average 12-month target
$57.00
▲ 3790.8% upside
Based on 1 analyst who set a price target on PAVM in the past 90 days. The average target is $57.00, with a high of $57.00 and a low of $57.00, compared with the last close of $1.47.
Low $57.00Avg $57.00High $57.00
Blue marker: last close $1.47
Highest target$57.00
Average target$57.00
Lowest target$57.00
Latest rating changes
Ascendiant CapitalTarget raised
Aug 27Buy$56 → $57
Ascendiant CapitalMaintained
Jun 8Buy$56
Date
Firm
Action
Rating
Price target
Aug 27
Ascendiant Capital
Target raised
Buy
$56 → $57
Jun 8
Ascendiant Capital
Maintained
Buy
$56
Loading…
Technical Analysis
PAVM · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 24% below its 20 day and 87% below its 50 day average. It is 320% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 34), near oversold. The nearest support is the Pivot S1 at $1.36, and the nearest resistance the Pivot at $1.55.
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 20.4%/day
Key levels
$28.4452 week high+1834.7%
$6.15200 day average+318.4%
$4.33Swing high (Sep 22)+194.6%
$3.98100 day average+170.7%
$2.7350 day average+85.7%
$1.8220 day average+23.8%
$1.66Pivot R1+12.9%
$1.55Pivot+5.4%
$1.47Last close
$1.36Pivot S1−7.5%
$1.1752 week low−20.4%
$1.17Swing low (Nov 11)−20.4%
Indicators
RSI (14)
34.08
Weak, oversold below 30
Neutral
MACD
-0.35
Above its signal line
Bullish
Stochastic
40.1
Middle of its range
Neutral
ADX (14)
50.9
Strong downtrend
Williams %R
-73.7
Oversold below −80, overbought above −20
Neutral
CCI (20)
-80.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−21.7%
Change over 10 sessions
Bearish
ATR (14)
$0.30
Typical daily range, 20.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 68.1%/day
Key levels
$28.4452 week high+1834.7%
$6.15200 day average+318.4%
$4.33Swing high (Sep 22)+194.6%
$3.98100 day average+170.7%
$2.7350 day average+85.7%
$1.8220 day average+23.8%
$1.66Pivot R1+12.9%
$1.55Pivot+5.4%
$1.47Last close
$1.36Pivot S1−7.5%
$1.1752 week low−20.4%
$1.17Swing low (Nov 11)−20.4%
Indicators
RSI (14)
22.69
Oversold below 30
Oversold
MACD
-1.49
Below its signal line
Bearish
Stochastic
6.1
Near the bottom of its range
Oversold
ADX (14)
22.2
Weak trend
Williams %R
-93.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-106.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−65.0%
Change over 10 sessions
Bearish
ATR (14)
$1.00
Typical daily range, 68.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PAVM
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how PAVM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow PAVM usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PAVM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PAVM is in one of them and how their past PAVM trades turned out.
PAVmed is a New York based company that works in medical devices, diagnostics and digital health. Its main product is the EsoGuard test, a DNA test run on cells collected with the EsoCheck device, which is offered to doctors, health systems, employers and patients to screen people with chronic acid reflux for esophageal precancer. Its Veris Health unit provides digital tools for cancer patients during and after treatment. The company is also developing PortIO, an implantable vascular access device.